Targeting glycans for cancer immunotherapy.

Antibody–lectin chimeras (AbLecs) outperform conventional antibody therapies in enhancing antitumor immune responses in cancer models.

• Why it matters: Glycans that contribute to immune suppression in cancer represent a promising but underexplored target for immunotherapy. Addressing this gap could improve treatment efficacy.
• What they did: Researchers developed AbLecs to bind and block glycans involved in immune suppression, testing their effects both in vitro and in vivo.
• The result: AbLecs significantly enhance antitumor immune responses, surpassing the performance of approved cancer drugs and conventional antibody therapies.